Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non-cash Items (2016 - 2025)

Lineage Cell Therapeutics' Non-cash Items history spans 14 years, with the latest figure at $6.2 million for Q4 2025.

  • For Q4 2025, Non-cash Items changed N/A year-over-year to $6.2 million; the TTM value through Dec 2025 reached $6.2 million, changed N/A, while the annual FY2025 figure was $6.2 million, N/A changed from the prior year.
  • Non-cash Items reached $6.2 million in Q4 2025 per LCTX's latest filing, down from $10.1 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $13.0 million in Q1 2023 to a low of $4000.0 in Q4 2023.
  • Average Non-cash Items over 5 years is $7.1 million, with a median of $8.0 million recorded in 2022.
  • Peak YoY movement for Non-cash Items: skyrocketed 9947.13% in 2021, then plummeted 99.71% in 2023.
  • A 5-year view of Non-cash Items shows it stood at $9.6 million in 2021, then plummeted by 85.79% to $1.4 million in 2022, then tumbled by 99.71% to $4000.0 in 2023, then surged by 137200.0% to $5.5 million in 2024, then grew by 12.89% to $6.2 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Non-cash Items are $6.2 million (Q4 2025), $10.1 million (Q3 2025), and $9.4 million (Q2 2025).